These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15595940)

  • 1. Health-related quality of life in blepharospasm or hemifacial spasm.
    Reimer J; Gilg K; Karow A; Esser J; Franke GH
    Acta Neurol Scand; 2005 Jan; 111(1):64-70. PubMed ID: 15595940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The validation of the disease-specific questionnaire for health-related quality of life in Thai patients with hemifacial spasm.
    Setthawatcharawanich S; Aui-aree N; Limapichart K; Satirapunya P; Phabphal K
    J Med Assoc Thai; 2008 Nov; 91(11):1691-7. PubMed ID: 19127791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
    Quagliato EM; Carelli EF; Viana MA
    Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Blepharospasm and hemifacial spasm treated with botulinum A toxin injection].
    Wang J; Lin S; Zhang X
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1998 Oct; 33(5):291-3. PubMed ID: 11717871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
    Thussu A; Barman CR; Prabhakar S
    Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin.
    Price J; O'Day J
    J Clin Neuroophthalmol; 1993 Mar; 13(1):67-71. PubMed ID: 8501266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemifacial spasm, quality of life and depression].
    Serrano-Dueñas M
    Rev Neurol; 1999 Dec 16-31; 29(12):1108-11. PubMed ID: 10652731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm.
    Hall TA; McGwin G; Searcey K; Xie A; Hupp SL; Owsley C; Kline LB
    Arch Ophthalmol; 2006 Jan; 124(1):116-9. PubMed ID: 16401794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical outcome and improvement in quality of life after microvascular decompression for hemifacial spasms: a case series assessment using a validated disease-specific scale.
    Ray DK; Bahgat D; McCartney S; Burchiel KJ
    Stereotact Funct Neurosurg; 2010; 88(6):383-9. PubMed ID: 20948243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in blepharospasm and hemifacial spasm.
    Tan EK; Seah A
    Arch Ophthalmol; 2007 Aug; 125(8):1141; author reply 1141. PubMed ID: 17698774
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment outcome correlates with knowledge of disease in hemifacial spasm.
    Tan EK; Hameed S; Fook-Chong S; Hussein K; Lum SY; Chan LL
    Clin Neurol Neurosurg; 2008 Sep; 110(8):813-7. PubMed ID: 18583029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of idiopathic blepharospasm and hemifacial spasm.
    Tsai CP; Chiu MC; Yen DJ; Guo YC; Yuan CL; Lee TC
    Acta Neurol Taiwan; 2005 Jun; 14(2):61-8. PubMed ID: 16008164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases.
    Ortisi E; Henderson HW; Bunce C; Xing W; Collin JR
    Eye (Lond); 2006 Aug; 20(8):916-22. PubMed ID: 16531977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin.
    Setthawatcharawanich S; Sathirapanya P; Limapichat K; Phabphal K
    Qual Life Res; 2011 Nov; 20(9):1519-23. PubMed ID: 21431990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
    Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
    Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing responsiveness of generic and specific health related quality of life measures in heart failure.
    Eurich DT; Johnson JA; Reid KJ; Spertus JA
    Health Qual Life Outcomes; 2006 Nov; 4():89. PubMed ID: 17125512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires.
    Petersen KD; Kronborg C; Gyrd-Hansen D; Dahl R; Larsen JN; Løwenstein H
    Allergy; 2008 Mar; 63(3):284-91. PubMed ID: 18269674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closely spaced stressful life events precede the onset of benign essential blepharospasm and hemifacial spasm.
    Johnson LN; Lapour RW; Johnson GM; Johnson PJ; Madsen RW; Hackley SA
    J Neuroophthalmol; 2007 Dec; 27(4):275-80. PubMed ID: 18090560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.